DMMDA-2

DMMDA-2

DMMDA-2 is a psychedelic and hallucinogenic drug, which is less commonly known as 2,5-dimethoxy-3,4-methylenedioxyamphetamine. This compound is a member of the DOx family of compounds which are known for their psychedelic effects. DMMDA-2 is a synthetic substance of the amphetamine class.

History

DMMDA-2 was first synthesized and studied by the team led by Alexander Shulgin. In his book PiHKAL, Shulgin listed the dosage of DMMDA-2 as 60-100mg and the duration as 6-8 hours. He describes the effects of DMMDA-2 as being quite similar to MDA, but with a shorter duration and less of an impact on color perception.

Pharmacology

The exact mechanism of action for DMMDA-2 is not fully understood. However, it is believed to work by increasing the release of serotonin in the brain and inhibiting its reuptake, similar to other psychedelic amphetamines. This leads to an overall increase in serotonergic neurotransmission, which is thought to be responsible for the drug's hallucinogenic effects.

Legal Status

As of 2021, DMMDA-2 is not specifically listed in the United Nations' drug control treaties, but it may be considered illegal in some countries under their analogue laws. In the United States, DMMDA-2 is not explicitly listed as a controlled substance, but possession or sale could potentially be prosecuted under the Federal Analogue Act.

See Also

• DOx
• PiHKAL
• Alexander Shulgin
• Psychedelic drug
• Hallucinogen
• Amphetamine

This article is a stub related to pharmacology. You can help WikiMD by expanding it!